lobbying_activities: 2822269

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2822269	fffbf069-66e0-4830-9119-2c95039df101	Q2	MARSHALL & POPP, LLC	401105121	PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA	2022	second_quarter	PHA	Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S. 2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.	HOUSE OF REPRESENTATIVES,SENATE	40000		0	0	2022-07-17T08:32:03-04:00